NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

At the same time, and also based on the Destiny-Breast06 trial, Daiichi announced that the European Medicines ... for Medicinal Products for Human Use," Daiichi Sankyo explained.

MUNICH--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE ... to enhance the long-term value of their products. DSE has agreed to pay Esperion ...

Daiichi Sankyo – which licenses rights to Nexletol in some markets – disagrees. It is on the hook for the milestone payment once the CLEAR results are added into the drug’s label in Europe ...

Among the first presentations at the European Society for Medical Oncology (ESMO) meeting that kicked off today, were results ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

At the same time, and also based on the Destiny-Breast06 trial, Daiichi announced that the European Medicines Agency validated ... by the EMA's Committee for Medicinal Products for Human Use," Daiichi ...